Gyre Therapeutics (NASDAQ:GYRE) Shares Up 6.6%

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price traded up 6.6% during trading on Friday . The stock traded as high as $12.60 and last traded at $12.60. 44,962 shares changed hands during trading, a decline of 38% from the average session volume of 72,367 shares. The stock had previously closed at $11.82.

Gyre Therapeutics Trading Up 2.6 %

The company has a fifty day simple moving average of $12.70 and a two-hundred day simple moving average of $14.36.

Gyre Therapeutics (NASDAQ:GYRE) last posted its earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $25.23 million during the quarter. On average, equities research analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Insider Activity

In related news, Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the completion of the transaction, the director now directly owns 1,636 shares of the company’s stock, valued at $19,632. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.92% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in Gyre Therapeutics in the 2nd quarter worth approximately $166,000. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics during the second quarter worth $123,000. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics during the second quarter worth $218,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics during the second quarter valued at $220,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.